Example response
The response this call returned, captured 2026-10-07 12:44:45 UTC.
{
"portal": {
"provenance": "third-party-supplier",
"serviceId": "pmic-pharma-signals",
"schemaCheck": "unchecked"
},
"data": {
"service": "pmic-pharma-signals",
"pack_version": "0.5.0",
"vertical": "company-safety",
"title": "Company drug safety",
"question": "Are safety signals rising for this drug maker, and what has the FDA reported lately?",
"entity": {
"entity_id": "lly",
"name": "Eli Lilly and Co.",
"ticker": "LLY",
"industry": "pharma"
},
"horizon": "365d",
"status": "ok",
"score": 40,
"label": "elevated",
"previous_score": null,
"change": null,
"trend": "escalating",
"trend_basis": "input_trends",
"summary": "Company drug safety for Eli Lilly and Co.: 40/100, elevated, trend escalating (from its inputs' latest moves). Strongest input: Drug recalls naming Eli Lilly, weekly at 50; weakest: FAERS adverse event reports for Eli Lilly products, weekly at 27. Based on 3 of 3 inputs.",
"scale": {
"high": "60+ = calm",
"mid": "41-59 = normal",
"low": "40 or less = elevated",
"note": "Higher score means calmer than usual for this company: fewer recalls and adverse event reports, more approvals. Label changes are a watch item."
},
"drivers": [
{
"series_id": "openfda:LLY:adverse_event_reports_weekly",
"label": "FAERS adverse event reports for Eli Lilly products, weekly",
"score": 27,
"summary": "FAERS adverse event reports for Eli Lilly products, weekly (lly) was 2302.0 count as of 2026-06-22, up 34.0% over 30 days. That level sits at the 79th percentile of the trailing window (z +0.65, 42 points). Composite 27/100 (higher reads weaker, so the score is inverted). Source openFDA (drug enforcement, drugs@FDA, FAERS); freshness 0/100.",
"citation_url": "https://api.fda.gov/drug/event.json?search=receivedate:[20250901+TO+20261006]+AND+patient.drug.openfda.manufacturer_name:\"Eli+Lilly\"&count=receivedate"
},
{
"series_id": "openfda:LLY:approvals_weekly",
"label": "Original FDA approvals (NDA, BLA, ANDA) for Eli Lilly, weekly",
"score": 48,
"summary": "Original FDA approvals (NDA, BLA, ANDA) for Eli Lilly, weekly (lly) was 0.0000 count as of 2026-09-28, down 100.0% over 365 days. That level sits at the 48th percentile of the trailing window (z -0.20, 52 points). Composite 48/100 (higher reads stronger). Source openFDA (drug enforcement, drugs@FDA, FAERS); freshness 100/100.",
"citation_url": "https://api.fda.gov/drug/drugsfda.json?search=submissions.submission_type:\"ORIG\"+AND+submissions.submission_status:\"AP\""
},
{
"series_id": "openfda:LLY:drug_recalls_weekly",
"label": "Drug recalls naming Eli Lilly, weekly",
"score": 50,
"summary": "Drug recalls naming Eli Lilly, weekly (lly) was 0.0000 count as of 2026-09-28. That level sits at the 50th percentile of the trailing window (z +0.00, 52 points). Composite 50/100 (higher reads weaker, so the score is inverted). Source openFDA (drug enforcement, drugs@FDA, FAERS); freshness 100/100.",
"citation_url": "https://api.fda.gov/drug/enforcement.json?search=report_date:[20250831+TO+20261005]+AND+recalling_firm:\"Eli+Lilly\"&count=report_date"
}
],
"risk_flags": [
"stale_data"
],
"confidence": {
"score": 82,
"label": "high"
},
"coverage": {
"scored": 3,
"inputs": 3,
"weight_share": 1
},
"inputs": [
{
"series_id": "openfda:LLY:drug_recalls_weekly",
"label": "Drug recalls naming Eli Lilly, weekly",
"entity_id": "lly",
"weight": 2,
"direction": -1,
"value": {
"current": 0,
"unit": "count",
"as_of": "2026-09-28",
"transformed": 0
},
"changes_pct": {
"7d": null,
"30d": null,
"90d": null,
"365d": null
},
"hub_trend": "flat",
"confidence": {
"score": 96,
"label": "high"
},
"risk_flags": [
"single_source"
],
"summary": "Drug recalls naming Eli Lilly, weekly (lly) was 0.0000 count as of 2026-09-28. That level sits at the 50th percentile of the trailing window (z +0.00, 52 points). Composite 50/100 (higher reads weaker, so the score is inverted). Source openFDA (drug enforcement, drugs@FDA, FAERS); freshness 100/100.",
"citation_url": "https://api.fda.gov/drug/enforcement.json?search=report_date:[20250831+TO+20261005]+AND+recalling_firm:\"Eli+Lilly\"&count=report_date",
"source": "openfda",
"role": "input",
"scoring": "hub_composite",
"score": 50,
"previous_score": null
},
{
"series_id": "openfda:LLY:adverse_event_reports_weekly",
"label": "FAERS adverse event reports for Eli Lilly products, weekly",
"entity_id": "lly",
"weight": 2,
"direction": -1,
"value": {
"current": 2302,
"unit": "count",
"as_of": "2026-06-22",
"transformed": 2302
},
"changes_pct": {
"7d": 2.8138,
"30d": 33.993,
"90d": 5.8878,
"365d": null
},
"hub_trend": "up",
"confidence": {
"score": 61,
"label": "medium"
},
"risk_flags": [
"stale_data",
"revised_by_source",
"single_source"
],
"summary": "FAERS adverse event reports for Eli Lilly products, weekly (lly) was 2302.0 count as of 2026-06-22, up 34.0% over 30 days. That level sits at the 79th percentile of the trailing window (z +0.65, 42 points). Composite 27/100 (higher reads weaker, so the score is inverted). Source openFDA (drug enforcement, drugs@FDA, FAERS); freshness 0/100.",
"citation_url": "https://api.fda.gov/drug/event.json?search=receivedate:[20250901+TO+20261006]+AND+patient.drug.openfda.manufacturer_name:\"Eli+Lilly\"&count=receivedate",
"source": "openfda",
"role": "input",
"scoring": "hub_composite",
"score": 27,
"previous_score": null
},
{
"series_id": "openfda:LLY:approvals_weekly",
"label": "Original FDA approvals (NDA, BLA, ANDA) for Eli Lilly, weekly",
"entity_id": "lly",
"weight": 1,
"direction": 1,
"value": {
"current": 0,
"unit": "count",
"as_of": "2026-09-28",
"transformed": 0
},
"changes_pct": {
"7d": -100,
"30d": null,
"90d": null,
"365d": -100
},
"hub_trend": "flat",
"confidence": {
"score": 96,
"label": "high"
},
"risk_flags": [
"single_source"
],
"summary": "Original FDA approvals (NDA, BLA, ANDA) for Eli Lilly, weekly (lly) was 0.0000 count as of 2026-09-28, down 100.0% over 365 days. That level sits at the 48th percentile of the trailing window (z -0.20, 52 points). Composite 48/100 (higher reads stronger). Source openFDA (drug enforcement, drugs@FDA, FAERS); freshness 100/100.",
"citation_url": "https://api.fda.gov/drug/drugsfda.json?search=submissions.submission_type:\"ORIG\"+AND+submissions.submission_status:\"AP\"",
"source": "openfda",
"role": "input",
"scoring": "hub_composite",
"score": 48,
"previous_score": null
}
],
"watch": [
{
"series_id": "openfda:LLY:label_updates_weekly",
"label": "Drug label (SPL) versions effective for Eli Lilly products, weekly",
"entity_id": "lly",
"weight": 1,
"direction": 0,
"value": {
"current": 0,
"unit": "count",
"as_of": "2026-09-28",
"transformed": 0
},
"changes_pct": {
"7d": null,
"30d": -100,
"90d": -100,
"365d": null
},
"hub_trend": "down",
"confidence": {
"score": 96,
"label": "high"
},
"risk_flags": [
"sharp_move",
"single_source"
],
"summary": "Drug label (SPL) versions effective for Eli Lilly products, weekly (lly) was 0.0000 count as of 2026-09-28, down 100.0% over 30 days. That level sits at the 36th percentile of the trailing window (z -0.42, 52 points). Composite 56/100 (neutral series: the score measures how unusual the reading is). Source openFDA (drug enforcement, drugs@FDA, FAERS); freshness 100/100.",
"citation_url": "https://api.fda.gov/drug/label.json?search=effective_time:[20250831+TO+20261005]+AND+openfda.manufacturer_name:\"Eli+Lilly\"&count=effective_time",
"source": "openfda",
"role": "watch",
"scoring": "hub_unusualness",
"score": 56,
"previous_score": null
}
],
"citations": [
{
"series_id": "openfda:LLY:drug_recalls_weekly",
"label": "Drug recalls naming Eli Lilly, weekly",
"as_of": "2026-09-28",
"url": "https://api.fda.gov/drug/enforcement.json?search=report_date:[20250831+TO+20261005]+AND+recalling_firm:\"Eli+Lilly\"&count=report_date",
"source": "openfda"
},
{
"series_id": "openfda:LLY:adverse_event_reports_weekly",
"label": "FAERS adverse event reports for Eli Lilly products, weekly",
"as_of": "2026-06-22",
"url": "https://api.fda.gov/drug/event.json?search=receivedate:[20250901+TO+20261006]+AND+patient.drug.openfda.manufacturer_name:\"Eli+Lilly\"&count=receivedate",
"source": "openfda"
},
{
"series_id": "openfda:LLY:approvals_weekly",
"label": "Original FDA approvals (NDA, BLA, ANDA) for Eli Lilly, weekly",
"as_of": "2026-09-28",
"url": "https://api.fda.gov/drug/drugsfda.json?search=submissions.submission_type:\"ORIG\"+AND+submissions.submission_status:\"AP\"",
"source": "openfda"
},
{
"series_id": "openfda:LLY:label_updates_weekly",
"label": "Drug label (SPL) versions effective for Eli Lilly products, weekly",
"as_of": "2026-09-28",
"url": "https://api.fda.gov/drug/label.json?search=effective_time:[20250831+TO+20261005]+AND+openfda.manufacturer_name:\"Eli+Lilly\"&count=effective_time",
"source": "openfda"
}
],
"method": {
"version": "pmic-vertical/1.0",
"docs": "https://github.com/organiccryptoyyc/pocket-agentic-services/blob/main/pmic/packs/README.md"
},
"recent_events": [
{
"source_id": "ctgov",
"entity_id": "lly",
"event_type": "trial_stopped",
"event_time": "2026-09-23",
"title": "terminated trial NCT06220669: A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis",
"severity": "low",
"source_url": "https://clinicaltrials.gov/study/NCT06220669",
"fetch_time": "2026-10-04T21:19:43.127Z",
"detail": {
"nct_id": "NCT06220669",
"status": "TERMINATED",
"phases": [
"PHASE2"
]
}
},
{
"source_id": "openfda",
"entity_id": "lly",
"event_type": "drug_approval",
"event_time": "2026-09-23",
"title": "Original approval of ONSWIK (BLA761408) for ELI LILLY AND CO",
"severity": "medium",
"source_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761408",
"fetch_time": "2026-10-04T15:01:55.799Z",
"detail": {
"application_number": "BLA761408",
"sponsor_name": "ELI LILLY AND CO",
"brand_name": "ONSWIK",
"review_priority": "STANDARD",
"submission_class": "Type 1 - New Molecular Entity"
}
},
{
"source_id": "sec",
"entity_id": "lly",
"event_type": "insider_form4",
"event_time": "2026-09-22",
"title": "4 filed 2026-09-22 for period 2026-09-21",
"severity": "low",
"source_url": "https://www.sec.gov/Archives/edgar/data/59478/000131021526000017/xslF345X06/wk-form4_1790107902.xml",
"fetch_time": "2026-10-04T15:01:55.799Z",
"detail": {
"form": "4",
"items": null,
"report_date": "2026-09-21",
"primary_document": "xslF345X06/wk-form4_1790107902.xml",
"cik": 59478
}
},
{
"source_id": "sec",
"entity_id": "lly",
"event_type": "insider_form4",
"event_time": "2026-09-22",
"title": "4 filed 2026-09-22 for period 2026-09-21",
"severity": "low",
"source_url": "https://www.sec.gov/Archives/edgar/data/59478/000005947826000089/xslF345X06/wk-form4_1790107969.xml",
"fetch_time": "2026-10-04T15:01:55.799Z",
"detail": {
"form": "4",
"items": null,
"report_date": "2026-09-21",
"primary_document": "xslF345X06/wk-form4_1790107969.xml",
"cik": 59478
}
},
{
"source_id": "sec",
"entity_id": "lly",
"event_type": "insider_form4",
"event_time": "2026-09-22",
"title": "4 filed 2026-09-22 for period 2026-09-21",
"severity": "low",
"source_url": "https://www.sec.gov/Archives/edgar/data/59478/000005947826000091/xslF345X06/wk-form4_1790108065.xml",
"fetch_time": "2026-10-04T15:01:55.799Z",
"detail": {
"form": "4",
"items": null,
"report_date": "2026-09-21",
"primary_document": "xslF345X06/wk-form4_1790108065.xml",
"cik": 59478
}
},
{
"source_id": "sec",
"entity_id": "lly",
"event_type": "insider_form4",
"event_time": "2026-09-22",
"title": "4 filed 2026-09-22 for period 2026-09-21",
"severity": "low",
"source_url": "https://www.sec.gov/Archives/edgar/data/59478/000126238826000018/xslF345X06/wk-form4_1790108122.xml",
"fetch_time": "2026-10-04T15:01:55.799Z",
"detail": {
"form": "4",
"items": null,
"report_date": "2026-09-21",
"primary_document": "xslF345X06/wk-form4_1790108122.xml",
"cik": 59478
}
},
{
"source_id": "ctgov",
"entity_id": "lly",
"event_type": "trial_stopped",
"event_time": "2026-09-21",
"title": "terminated trial NCT07085468: A Study of LY3549492 in Healthy Weight Adult Participants",
"severity": "low",
"source_url": "https://clinicaltrials.gov/study/NCT07085468",
"fetch_time": "2026-10-04T21:19:43.127Z",
"detail": {
"nct_id": "NCT07085468",
"status": "TERMINATED",
"phases": [
"PHASE2"
]
}
},
{
"source_id": "ctgov",
"entity_id": "lly",
"event_type": "trial_stopped",
"event_time": "2026-09-14",
"title": "terminated trial NCT07152002: A Study of LY4064912 in Healthy Participants and With Overweight or Obesity",
"severity": "low",
"source_url": "https://clinicaltrials.gov/study/NCT07152002",
"fetch_time": "2026-10-04T21:19:43.127Z",
"detail": {
"nct_id": "NCT07152002",
"status": "TERMINATED",
"phases": [
"PHASE1"
]
}
},
{
"source_id": "sec",
"entity_id": "lly",
"event_type": "insider_form4",
"event_time": "2026-09-11",
"title": "4 filed 2026-09-11 for period 2025-09-22",
"severity": "low",
"source_url": "https://www.sec.gov/Archives/edgar/data/59478/000203208926000004/xslF345X06/wk-form4_1789157763.xml",
"fetch_time": "2026-10-04T15:01:55.799Z",
"detail": {
"form": "4",
"items": null,
"report_date": "2025-09-22",
"primary_document": "xslF345X06/wk-form4_1789157763.xml",
"cik": 59478
}
},
{
"source_id": "ctgov",
"entity_id": "lly",
"event_type": "trial_stopped",
"event_time": "2026-09-09",
"title": "terminated trial NCT06916143: Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduce",
"severity": "low",
"source_url": "https://clinicaltrials.gov/study/NCT06916143",
"fetch_time": "2026-10-04T21:19:43.127Z",
"detail": {
"nct_id": "NCT06916143",
"status": "TERMINATED",
"phases": [
"PHASE1"
]
}
},
{
"source_id": "ctgov",
"entity_id": "lly",
"event_type": "trial_stopped",
"event_time": "2026-09-08",
"title": "withdrawn trial NCT06598631: Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease",
"severity": "low",
"source_url": "https://clinicaltrials.gov/study/NCT06598631",
"fetch_time": "2026-10-04T21:19:43.127Z",
"detail": {
"nct_id": "NCT06598631",
"status": "WITHDRAWN",
"phases": [
"PHASE2"
]
}
},
{
"source_id": "ctgov",
"entity_id": "lly",
"event_type": "trial_stopped",
"event_time": "2026-09-08",
"title": "withdrawn trial NCT05580250: A Study of LY3526318 in Healthy Male Japanese Participants",
"severity": "low",
"source_url": "https://clinicaltrials.gov/study/NCT05580250",
"fetch_time": "2026-10-04T21:19:43.127Z",
"detail": {
"nct_id": "NCT05580250",
"status": "WITHDRAWN",
"phases": [
"PHASE1"
]
}
},
{
"source_id": "sec",
"entity_id": "lly",
"event_type": "insider_form4",
"event_time": "2026-09-04",
"title": "4 filed 2026-09-04 for period 2026-09-02",
"severity": "low",
"source_url": "https://www.sec.gov/Archives/edgar/data/59478/000195597226000008/xslF345X06/wk-form4_1788553030.xml",
"fetch_time": "2026-10-04T15:01:55.799Z",
"detail": {
"form": "4",
"items": null,
"report_date": "2026-09-02",
"primary_document": "xslF345X06/wk-form4_1788553030.xml",
"cik": 59478
}
},
{
"source_id": "sec",
"entity_id": "lly",
"event_type": "insider_form4",
"event_time": "2026-09-04",
"title": "4 filed 2026-09-04 for period 2026-09-02",
"severity": "low",
"source_url": "https://www.sec.gov/Archives/edgar/data/59478/000186105226000006/xslF345X06/wk-form4_1788553126.xml",
"fetch_time": "2026-10-04T15:01:55.799Z",
"detail": {
"form": "4",
"items": null,
"report_date": "2026-09-02",
"primary_document": "xslF345X06/wk-form4_1788553126.xml",
"cik": 59478
}
},
{
"source_id": "ctgov",
"entity_id": "lly",
"event_type": "trial_stopped",
"event_time": "2026-09-02",
"title": "terminated trial NCT04396236: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine",
"severity": "medium",
"source_url": "https://clinicaltrials.gov/study/NCT04396236",
"fetch_time": "2026-10-04T21:19:43.127Z",
"detail": {
"nct_id": "NCT04396236",
"status": "TERMINATED",
"phases": [
"PHASE3"
]
}
},
{
"source_id": "ctgov",
"entity_id": "lly",
"event_type": "trial_stopped",
"event_time": "2026-08-31",
"title": "terminated trial NCT07030868: A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes",
"severity": "low",
"source_url": "https://clinicaltrials.gov/study/NCT07030868",
"fetch_time": "2026-10-04T21:19:43.127Z",
"detail": {
"nct_id": "NCT07030868",
"status": "TERMINATED",
"phases": [
"PHASE2"
]
}
},
{
"source_id": "sec",
"entity_id": "lly",
"event_type": "insider_form4",
"event_time": "2026-08-18",
"title": "4 filed 2026-08-18 for period 2026-08-17",
"severity": "low",
"source_url": "https://www.sec.gov/Archives/edgar/data/59478/000178605426000006/xslF345X06/wk-form4_1787084453.xml",
"fetch_time": "2026-10-04T15:01:55.799Z",
"detail": {
"form": "4",
"items": null,
"report_date": "2026-08-17",
"primary_document": "xslF345X06/wk-form4_1787084453.xml",
"cik": 59478
}
},
{
"source_id": "sec",
"entity_id": "lly",
"event_type": "insider_form4",
"event_time": "2026-08-18",
"title": "4 filed 2026-08-18 for period 2026-08-17",
"severity": "low",
"source_url": "https://www.sec.gov/Archives/edgar/data/59478/000131021526000015/xslF345X06/wk-form4_1787084504.xml",
"fetch_time": "2026-10-04T15:01:55.799Z",
"detail": {
"form": "4",
"items": null,
"report_date": "2026-08-17",
"primary_document": "xslF345X06/wk-form4_1787084504.xml",
"cik": 59478
}
},
{
"source_id": "sec",
"entity_id": "lly",
"event_type": "insider_form4",
"event_time": "2026-08-18",
"title": "4 filed 2026-08-18 for period 2026-08-17",
"severity": "low",
"source_url": "https://www.sec.gov/Archives/edgar/data/59478/000005947826000085/xslF345X06/wk-form4_1787084560.xml",
"fetch_time": "2026-10-04T15:01:55.799Z",
"detail": {
"form": "4",
"items": null,
"report_date": "2026-08-17",
"primary_document": "xslF345X06/wk-form4_1787084560.xml",
"cik": 59478
}
},
{
"source_id": "sec",
"entity_id": "lly",
"event_type": "insider_form4",
"event_time": "2026-08-18",
"title": "4 filed 2026-08-18 for period 2026-08-17",
"severity": "low",
"source_url": "https://www.sec.gov/Archives/edgar/data/59478/000005947826000087/xslF345X06/wk-form4_1787084623.xml",
"fetch_time": "2026-10-04T15:01:55.799Z",
"detail": {
"form": "4",
"items": null,
"report_date": "2026-08-17",
"primary_document": "xslF345X06/wk-form4_1787084623.xml",
"cik": 59478
}
}
]
}
}